SCHEMBL2883520

SCHEMBL2883520

CC[Si](CC)(CC)OC1CC(C(=O)O)Cc2cccnc21

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
FAAH O00519 2/20 0.32
BRD4 O60885 1/20 0.32
SLC18A3 Q16572 1/20 0.31
ELANE P08246 1/20 0.31
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31
OPRL1 P41146 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP2C19 P33261 1/20 0.31
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882492 0.82 TSHR (0.36) FAAHSLC18A3L3MBTL1OPRL1KDM4E
SCHEMBL2882359 0.80 OPRL1 (0.36) DRD2DRD3OPRL1
SCHEMBL2882361 0.80 OPRL1 (0.36) DRD2DRD3OPRL1
SCHEMBL2883233 0.80 OPRL1 (0.36) DRD2DRD3OPRL1
SCHEMBL2878241 0.74 OPRL1 (0.40) FAAHL3MBTL1OPRL1KDM4ECYP2C19
SCHEMBL924248 0.73 CYP2C19 (0.42) BRD4ALDH1A1L3MBTL1KDM4ECYP2C19
SCHEMBL12975917 0.73 CYP2C19 (0.39) BRD4ALDH1A1L3MBTL1KDM4ECYP2C19
SCHEMBL2880299 0.71 OPRL1 (0.35) FAAHOPRL1KDM4ECYP2C19
SCHEMBL12907341 0.68 CYP2C19 (0.44) BRD4ALDH1A1L3MBTL1KDM4ECYP2C19
SCHEMBL369170 0.65 KDM4E (0.41) DPP8DPP9FAAHALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 DPP8 1141/4885DPP9 1325/4885FAAH 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.